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Abstract
Purpose To retrospectively analyze the evolution of indeterminate hepatocellular nodules in cirrhotic patients on serial Gd-
EOB-DPTA-enhanced MRI, and to identify predictors of HCC development.
Materials and methods This IRB approved study included 33 cirrhotic patients with 69 indeterminate hepatocellular nodules 
(mean diameter 1.1 cm) at baseline Gd-EOB-DPTA-enhanced MRI and a Gd-EOB-DPTA-enhanced-MRI follow-up of at 
least 2 years. Two radiologists evaluated size and signal intensity of each nodule at baseline and follow-up. Age, cirrhosis 
etiology, and HCC history were recorded. Data were compared between nodules that became HCCs at follow-up (HCC) and 
those that did not (no-HCC).
Results On follow-up, 5/69 nodules became HCCs and 64/69 showed indeterminate characteristics. HCC history was more 
frequently found in HCCs than in no-HCCs. Age, sex, and cirrhosis etiology were not significantly different between HCCs 
and no-HCCs. HCCs had a significantly greater baseline diameter and increase in size than no-HCCs. Hepatobiliary phase 
hypointensity was significantly more common in HCCs than in no-HCCs. Multivariate regression analysis showed that 
increase in size (OR 10.48; sensitivity, 100%; specificity, 81.2%; p < 0.001) and hepatobiliary phase hypointensity (OR 1.02; 
sensitivity, 100%; specificity, 78.1%; p < 0.001) was associated with HCC development.
Conclusion Indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients rarely became 
HCCs. Hepatobiliary phase hypointensity had a weak association with HCC development.
Keywords HCC · Indeterminate hepatocellular nodule · Cirrhosis · Gd-EOB-DTPA · Liver MRI
Introduction
Current diagnosis and management of hepatocellular car-
cinoma (HCC) are largely guided by imaging results. The 
number and size of HCC nodules influence treatment deci-
sions, and access to liver transplantation list [1, 2]. Thus, 
stringent criteria for a non-invasive diagnosis of HCC are 
mandatory [1, 2]. The American Association for the Study 
of Liver Disease (ASSLD) 2010 guidelines recommend that 
a non-invasive diagnosis of HCC in patients with chronic 
liver disease can be done at contrast-enhanced computed 
tomography (CT) or magnetic resonance imaging (MRI) if 
a nodule larger than 1 cm in diameter shows enhancement 
on hepatic arterial phase with subsequent wash-out on por-
tal venous and/or delayed phase [1]. Using these criteria, 
MRI specificity is approximately 90% for 1–1.9 cm HCCs 
and approximately 100% for > 2-cm HCCs [3, 4]. These 
differences are related to vascular tumor changes during 
hepatocarcinogenesis, which result in an initial decrease in 
normal portal and arterial supply, subsequently followed by 
an increase in abnormal arterial supply via newly formed, 
abnormal, arteries [5]. Hepatocellular nodules without typi-
cal imaging features of HCC are considered indeterminate 
by ASSLD 2010 guidelines, and a second study (the other of 
CT or MRI) or nodule biopsy is recommended [1]. With the 
advent of Gd-EOB-DTPA, the ability of MRI to detect HCC 
nodules has increased, but in parallel, a growing number of 
hepatocellular nodules with indeterminate characteristics 
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are being detected in the cirrhotic liver [6–8]. Most inde-
terminate hepatocellular nodules represent regenerative 
or dysplastic nodules, but a diagnosis of HCC cannot be 
ruled-out in almost all cases. In a radio-pathologic correla-
tion study including 111 indeterminate hepatocellular nod-
ules on Gd-EOB-DTPA MRI, Golfieri et al. have found 60 
benign lesions, 41 premalignant lesions (high-grade dysplas-
tic nodules/early HCC), and 10 HCCs, and concluded that 
hepatobiliary phase hypointensity is the stronger marker of 
malignancy [9]. The latter observation is in accordance with 
a paper by Kumada et al., which have reported that approxi-
mately one quarter of Gd-EOB-DTPA hepatobiliary phase 
hypointense hepatocellular nodules became hypervascular 
HCCs at follow-up [10]. Moreover, Kim et al. have found 
that hyperintensity on diffusion-weighted (DW) images 
in hypovascular hepatobiliary phase hypointense nodules 
increased the risk of progression to hypervascular HCCs 
[11]. However, these and similar studies have focused on 
nodules showing hypointensity on hepatobiliary phase and 
on their risk of HCC transformation. Other nodule imaging 
characteristics have not been extensively evaluated. To the 
best of our knowledge, there is only one study, which had 
specifically investigated the significance of hyperintense 
nodules on T1-weighted images [12].
Thus, the purpose of this study was to retrospectively 
analyze the evolution of indeterminate hepatocellular nod-
ules of any type on serial Gd-EOB-DPTA-enhanced MRI in 
cirrhotic patients, and to identify nodule characteristics that 
allow prediction of HCC development.
Materials and methods
Study population
This retrospective study was performed in a large, referral 
hospital for hepatobiliary diseases (Policlinico Paolo Giac-
cone, University of Palermo). Institution review board of 
our hospital approved this study, and waived the need for 
patient informed consent because of the retrospective nature 
of the study.
The study coordinator (F.A., a radiology fellow with 
8 years of experience) searched our radiology database 
to identify all cirrhotic patients who underwent Gd-
EOB-DPTA-enhanced MRI of the liver between January 
2009 and April 2015. To be included in this study, patients 
were required to have at least one hepatocellular nodule with 
indeterminate characteristics on cirrhotic liver at baseline 
Gd-EOB-DTPA-enhanced MRI, a mean baseline diameter 
of at least 5 mm. Indeterminate hepatocellular nodules were 
defined as those nodules that did not fulfill the non-inva-
sive diagnostic criteria for HCC diagnosis according to the 
ASSLD 2010 guidelines.
A total of 98 patients were identified
Of these, 55 were excluded for the following reasons: no 
Gd-EOB-DTPA MRI follow-up (n = 25), Gd-EOB-DTPA 
MRI follow-up of less than 24 months (n = 10), any sort 
of treatment of the indeterminate hepatocellular nodule 
(n = 12), indeterminate hepatocellular nodule measuring 
less than 5 mm in diameter (n = 15), cholangiocarcinoma 
(n = 2), and motion artifacts, which made the examina-
tions non-diagnostic (n = 1). Of the 10 who had less than 
24-month follow-up, no nodule become hypervascular 
HCC at at multi-detector row CT or MRI follow-up or was 
proved to be HCC at pathology. In the presence of multi-
ple hepatocellular indeterminate nodules, a maximum of 
three was selected per patient. Thus, the final study popu-
lation was composed by 33 consecutive patients (mean 
age 64.9 years; range 45–76 years) with 69 indeterminate 
hepatocellular nodules. Twenty-four were males (mean age 
65.7 years; range 45–72) and 9 were females (mean age 
63, years; range 47–76). Fourteen patients had one nodule, 
7 patients had 2 nodules, and 13 patients had three nod-
ules. The etiology of cirrhosis was hepatitis C infection in 
27 patients (82%), hepatitis B infection in three patients 
(10%), and both in three patients (10%). The diagnosis of 
cirrhosis was made on the basis of histological findings in 
eight patients and combined clinical features and labora-
tory results in 25 patients.
MR imaging protocol
MR imaging was performed on one of the two 1.5 T MR 
scanners available at our institution (Signa Excite, General 
Electric, Healthcare; Intera Achieva, Philips Healthcare) 
equipped with a body-phased array coil. All MR images 
were acquired using parallel imaging sensitivity encoding 
with a reduction factor of two. The imaging protocol for 
both scanners included axial T2-weighted turbo or fast 
spin-echo (with and without fat saturation) sequences, 
axial dual gradient-recalled echo (GRE) T1-weighted 
sequence, axial diffusion-weighted (DW) sequence using 
three b values (0, 150, and 800 s/mm2), and axial contrast-
enhanced three-dimensional T1-weighted GRE sequence 
with fat suppression. A bolus of 0.25 mmol/kg of GD-
EOB-DTPA (Primovist, Bayer, Berlin, Germany) was 
injected at a rate of 1, 1.5, or 2 mL/s, followed by 20-mL 
saline flush at the same injection rate, using an auto-
mated injector (Spectris; Medrad, Pittsburgh, PA, USA). 
Contrast-enhanced images are obtained immediately 
before and after contrast injection, on late hepatic arte-
rial phase at 20–35 s, portal-venous phase at 80 s, 3-min 
late, and 20-min hepatobiliary phases. An automated bolus 
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detection algorithm (MR Smart Prep; GE Medical Sys-
tems, Milwaukee, WI, USA) or a fluoroscopic triggering 
(Bolus-Trak; Philips Medical Systems, Best, The Neth-
erlands) was used to obtain an optimal hepatic arterial 
phase [13]. T2-weighted and DW sequences were obtained 
between the 3-min late and hepatobiliary phase to reduce 
the total examination time [14, 15]. Other MRI parameters 
are shown in Table 1.
Imaging analysis
All MR images were independently analyzed on a picture 
archiving and communication system (PACS) (Impax, 
Agfa-Gevaert, Mortsel, Belgium) by two radiologists (D.A 
and M.G., with 5 and 15 years of experience in liver imag-
ing, respectively). Discordance was resolved by consensus. 
Reviewers were informed that all patients were cirrhotic, 
but were blinded to all other patients’ clinical data. When 
multiple follow-up MRI examinations were available, only 
the latest one was evaluated. The size and signal intensity of 
each nodule were evaluated at baseline and follow-up MRI.
Nodule size was measured as the longest cross-sectional 
diameter. Change in size was considered significant if there 
was a minimum increase or decrease in nodule diameter 
of 5 mm [16]. Nodule signal intensity was evaluated on 
unenhanced T1- and T2-weighted sequences, as well as on 
high-b-value DW and contrast-enhanced sequences, and was 
classified as hypointense, isointense, or hyperintense to the 
surrounding liver. On the basis of signal intensity at baseline 
MRI, each nodule was classified into one of the following six 
groups (hereafter called baseline groups): 1, hypointense on 
hepatobiliary phase; 2, hyperintense on hepatobiliary phase; 
3, hypointense on 3-min late and hepatobiliary phase; 4, 
hyperintense on T1-weighted and hypointense on hepatobil-
iary phase; 5, hypointense on portal-venous, 3-min late and 
hepatobiliary phase; and 6, hyperintense on T1-weighted 
phase.
The coexistence of other (at least three) nodules with the 
same imaging appearance of the selected nodule at baseline 
MRI was recorded.
Diagnosis of HCC was done according to the ASSLD 
2010 guidelines criteria that require a minimum size of 
10 mm, and a typical enhancement pattern (i.e., arterial 
enhancement followed by venous wash-out) [1].
Medical charts were reviewed to determine whether any 
HCC exceeded the AASLD 2010 criteria for curative treat-
ment, which include a single HCC more than 5 cm in diam-
eter or ≤ 3 HCCs less than 3 cm [1].
Statistical analysis
Statistical analysis was performed at per nodule level. The 
dependency among nodules observed within the same 
patient was explicitly considered in the analysis.
Data were compared between nodules that became HCCs 
at follow-up (hereafter called HCC nodules) and those that 
did not (hereafter called no-HCC nodules) using the Fisher’s 
exact test for categorical variables and the generalized esti-
mating equations model (GEE), with binomial family and 
logit link, for continuous variables. Age, cirrhosis etiology, 
and history of HCC before the baseline MR examination 
were also considered as a variable.
Data were reported as count and percentage for qualita-
tive variables and as mean and standard deviation for con-
tinuous variables. A p value of < 0.05 was considered to 
indicate a statistically significant difference.
Table 1  MRI protocol
W weighted, FSE fast spin echo, GRE gradient-recalled echo, DWI diffusion-weighted imaging, 3D three-
dimensional, TSE turbo spin echo
Sequence T2-w TSE Dual T1-w GRE DWI 3D T1-w GRE
1.5 T Signa GE scanner
 TR/TE (ms) 4000/76 140/2.2–4.4 1600/72 3.8/1.2
 Flip angle (°) 150 70 90 12
 Field of view (cm) 35–40 × 35–40 35–40 × 35–40 35–40 × 35–40 35–40 × 35–40
 Matrix 256 × 224 256 × 160 144 × 192 256 × 256
 Section thickness (mm) 6 6 7 3
 Intersection gap (mm) – – 1 –
1.5 T Intera Philips scanner
 TR/TE (ms) 2500–8000/90 236/2–4.3 3448/64 4.5/2.2
 Flip angle (°) 90 80 90 10
 Field of view (cm) 35–40 × 35–40 35–40 × 35–40 35–40 × 35–40 35–40 × 35–40
 Matrix 320 × 320 240 × 256 256 × 120 208 × 256
 Section thickness (mm) 4 5 5 3
 Intersection gap (mm) 1 1 1 –
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Multivariate GEE model including all significant vari-
ables at the univariate analysis was used to identify inde-
pendent predictors of HCC development. The adjusted odds 
ratios (ORs) with respective 95% confidence intervals (CIs), 
sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) were reported. Statistical 
analysis was performed using a commercial statistical pack-
age software (Stata SE, versions 14.1; Stata, College Station, 
TX, USA).
Results
Study population
Of sixty-nine indeterminate hepatocellular nodules, only 5 
(7%) in five patients become hypervascular HCCs at follow-
up (Fig. 1). The remaining 64 of 69 (93%) nodules showed 
indeterminate characteristics (56 of 63, 87%), or disap-
peared (8 of 63, 13%) at follow-up (Fig. 2). The mean MRI 
follow-up was 805 days (range 785–2440 days). The mean 
time between the baseline MRI and HCC development was 
551 days (range 413–735). No-HCC exceeded the AASLD 
2010 criteria for curative treatment [1]. 
A history of HCC before the baseline MR examination 
was more frequently found in HCC nodules (4 of 5, 80%) 
than in no-HCC nodules (29 of 64, 45%) (p < 0.005).
There were no statistically significant differences in the 
age, sex, and etiology of cirrhosis between the HCC and 
no-HCC nodules.
Demographic and clinical data are summarized in 
Table 2.
Size
The mean nodule size was 1.1 cm (range 0.5–2 cm) at base-
line, and 1.2 cm (range 0–6.6 cm) at follow-up, with a mean 
change in size of 0.27 cm (range 0.14–2.6 cm). The HCC 
nodules had a greater mean baseline diameter than non-HCC 
nodules, and these differences were statistically significant.
The mean tumor diameter doubling time of HCC nodules 
was 595.25 days. Of the 64 no-HCC nodules, 12 of 64 (19%) 
increased in size at follow-up, 37 of 64 (58%) were stable 
in size, and 15 of 64 (23%) decreased in size. Among 12 
no-HCC nodules with increased size at follow-up, 10 of 12 
(83%) were high-grade dysplastic nodules and 2 of 12 (17%) 
were low-grade dysplastic nodules.
Diagnosis of no-HCC was confirmed by means of surgi-
cal resection (two high-grade dysplastic nodules) and fine-
needle biopsy (eight high-grade dysplastic nodules and two 
low-grade dysplastic nodules).
HCC nodules had a significantly greater mean change in 
size than no-HCC nodules. Details are shown in Table 3.
Fig. 1  HCC nodule in a 65-year-old man with HCV-related cirrhosis. 
a On baseline MRI, the nodule (arrow) shows hypointensity on hepa-
tobiliary phase. b, c On 15-month MR follow-up, the nodule shows 
enhancement on hepatic arterial phase (b) and wash-out on portal-
venous phase (b)
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Signal intensity characteristics
Hypointensity on hepatobiliary phase was significantly 
more common in HCC than in no-HCC nodules. Other 
baseline signal intensity characteristics of HCC nodules 
were not significantly different from that of no-HCC nod-
ules. However, there were trends toward HCC develop-
ment, which did not reach statistical significance among 
nodules that showed hypointensity on 3-min late phase. 
Details are shown in Table 3.
Multivariate analysis
Multivariate regression analysis included history of HCC, 
baseline size, increase in size, and hypointensity on hepa-
tobiliary phase. We found that increase in size [OR 10.48 
(95 CIs 2.99–36.74); sensitivity, 100%; specificity, 81.2%; 
PPV, 31.3%, NPV, 100%; p < 0.001], and hypointensity on 
hepatobiliary phase [OR 1.02 (95 CIs 0.21–5.05); sensi-
tivity, 100%; specificity, 78.1%; PPV, 16.7%; NPV, 100%; 
p = <0.001], were associated with HCC development. Other 
variables failed to achieve a statistical significance.
Discussion
In this study, we have analyzed the evolution of indetermi-
nate hepatocellular nodules in cirrhotic patients in serial Gd-
EOB-DPTA-enhanced MRI. We found that only few nodules 
became hypervascular HCCs at follow-up, and the majority 
of nodules showed indeterminate findings or disappeared 
at follow-up.
The frequency of HCC transformation of indeterminate 
hepatocellular nodules was in line with the previous results 
[17–19]. In a study using contrast-enhanced CT, Chung 
et al. have reported that 15 of 634 (2.4%) non-hypervascu-
lar, hypoattenuating, and hepatocellular nodules transformed 
into hypervascular HCCs on serial imaging follow-up [17]. 
Differences between our results and those by Chung et al. 
are probably related to the higher sensitivity of MRI com-
pared to CT in the diagnosis of HCC [20]. The observation 
that indeterminate hepatocellular nodules rarely become 
hypervascular HCCs is also supported by a study by Seki 
et al., which have reported that most dysplastic nodules dis-
appeared (15 of 33, 45%) or remained unchanged (14 of 
33, 42%) at follow-up [18]. The fact that dysplastic nodules 
rarely progress into HCCs has also been described by Farber 
et al. in a study using a rat model [19].
The HCC nodules had a slow grow on a serial imaging 
follow-up, suggesting that a 6–12-month follow-up is the 
best option for the management of indeterminate hepatocel-
lular nodules detected at Gd-EOB-DTPA-enhanced MRI. 
Nodule biopsy may represent an alternative option, but 
the invasiveness and risk of complications (e.g., bleeding) 
strongly limit its usage [21]. Of note, in our series, all no-
HCCs with increased size at follow-up were high- or low-
grade dysplastic nodules at pathology analysis.
Since the goal of screening cirrhotic patients is to detect 
HCC at an early stage, the second purpose of our study 
was to identify nodule characteristics that can predict 
HCC development [1, 22, 23]. We found that the only 
Fig. 2  No-HCC nodule in a 63-year-old man with HCV-related cir-
rhosis. a Baseline hepatobiliary phase MR image shows a hypoin-
tense nodule in the right hepatic lobe (arrow). b On 18-month hepato-
biliary phase MR image, the nodule is not appreciable
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baseline independent predictor of HCC development was 
the hepatobiliary phase hypointensity. Due to the obser-
vation of this feature in all HCCs, its application as inde-
pendent predictor of HCC development had a sensitivity 
of 100%. Hepatobiliary phase hypointensity was attrib-
uted to decreased organic anion-transporting polypeptide 
(OATP8) expression, which occurs during the multistep 
hepatocarcinogenesis in parallel with elevation of nodule 
malignancy grade, before the reduction of normal arterio-
portal inflow and elevation of abnormal arterial inflow 
[24]. This allowed us to speculate that hepatobiliary phase 
hypointense nodules, which subsequently became HCCs, 
might be high-grade dysplastic nodules or early HCCs [25, 
26]. In a study including sixty-six consecutive cirrhotic 
patients with seventy pathologically proved hepatocellular 
nodules, Lee et al. reported that well-differentiated HCCs 
showed more frequently hepatobiliary phase hypointensity 
than benign hepatocellular nodules [27]. However, in our 
series, hepatobiliary phase hypointensity had a specificity 
of 78% and a very week OR (1.2), because most hepatocel-
lular nodules showing hepatobiliary phase hypointensity 
remained indeterminate, or disappeared at follow-up. In 
view of this, hepatobiliary phase hypointensity might not 
necessarily suggest potential HCC transformation, and its 
application as a predictor of HCC development should be 
undertaken cautiously. This is supported by the fact that 
hepatobiliary phase hypointensity was considered by the 
Liver Imaging Reporting and Data System (LIRADS) as 
an ancillary feature that favors the diagnosis of HCC and 
not a major feature of HCC [28]. The fact that the hepato-
biliary phase hypointensity can be found in any non-hepat-
ocyte containing lesion (e.g., cysts and hemangiomas) 
further limits its application as an independent predictor 
for HCC development [28–30]. No-HCC nodules showing 
hepatobiliary phase hypointensity are likely regenerative 
or dysplastic nodules.
Another interesting result of our study was that, although 
HCC nodules had a greater mean baseline diameter than no-
HCC nodules, the baseline size was not a predictive factor 
for HCC development.
On the other hand, nodule increase in size significantly 
correlated with HCC transformation, and represented an 
independent predictor of HCC development. In our series, 
an increase in size was observed in all HCC- nodules and 
in few no-HCC nodules. Thus, it is crucial to pay particular 
attention and carefully observe those hepatocellular nodules, 
which show hepatobiliary phase hypointensity and increase 
in size.
This study had some limitations that should be pointed 
out. First, the number of indeterminate hepatocellular nod-
ules was relatively small. However, this reflects our clini-
cal practice, in which imaging follow-up is performed with 
different modalities and suspicious nodules are treated as 
soon as possible to prevent the development of untreatable 
HCCs. Second, pathologic analysis of all nodules was not 
performed. Therefore, we cannot exclude that some indeter-
minate hepatocellular nodules may be atypical HCCs. How-
ever, the probability that a no-HCC nodule with stable or 
decreased size at follow-up was an HCC was extremely low 
because of a long follow-up [31, 32]. Finally, there was no a 
control group of HCC nodules without indeterminate find-
ings at the previous Gd-EOB-DTPA-enhanced MR studies. 
Comparison of HCCs with and without indeterminate find-
ings at the previous Gd-EOB-DTPA-enhanced MR studies 
Table 2  Demographic and 
clinical features
Group A included nodules that showed indeterminate characteristics at follow-up. Group B included nod-
ules that disappeared at follow-up. Unless otherwise indicated, data are numbers. Data in parentheses are 
percentages. Data in parentheses are ranges
a Data are mean ± standard deviation
Parameter Final diagnosis
HCC (N = 5) No-HCC
Total (N = 64) Group A (N = 56) Group B (N = 8)
Agea 67 (56–78) 64.4 (41–82) 65.9 (41–82) 54.4 (44–63)
Sex
 Male 4 (80) 54 (84) 47 (84) 7 (87)
 Female 1 (20) 10 (16) 9 (16) 1(13)
Cirrhosis etiology
 Hepatitis C virus 5 (100) 48 (75) 40 (72) 8 (100)
 Hepatitis B virus – 13 (20) 13 (23) –
 Hepatitis C and B virus – 3 (5) 3 (5) –
History of HCC
 Yes 4 (80.0) 29 (45) 26 (46) 3 (37)
 No 1 (20.0) 35 (55) 30 (54) 5 (63)
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Table 3  Imaging features
Parameter Final diagnosis
HCC (N = 5) No-HCC
Total (N = 64) Group A (N = 56) Group B (N = 8)
Initial size (mm)a 20.4 ± 11.19 (12;40) 10.95 ± 5.04 (4;30) 11.43 ± 5.06 (4;30) 7.6 ± 3.54 (4;14)
Change in size (mm)a 10 ± 9.03 (5;26) − 0.48 ± 3.99 (− 14;12) 0.54 ± 2.8 (− 5;12) − 7.63 ± 3.54 (− 14;− 4)
Change in size
 Increased 5 (100) 12 (19) 12 (21) –
 Decreased – 15 (23) 7 (12) 8 (100)
 Stable – 37 (58) 37 (66) –
SI on T2-w phase
 Hypointense – – – –
 Isointense 5 (100) 64 (100) 56 (100) 8 (100)
 Hyperintense – – – –
SI on T2-w fat-sat phase
 Hypointense – – – –
 Isointense 5 (100) 64 (100) 56 (100) 8 (100)
 Hyperintense – – – –
SI on high-b-value DW phase
 Hypointense – – – –
 Isointense 5 (100) 64 (100) 56 (100) 8 (100)
 Hyperintense – – – –
SI on T1-w phase
 Hypointense – 3 (5) 3 (5) –
 Isointense 4 (80) 45 (70) 38 (68) 7 (87)
 Hyperintense 1 (20) 16 (25) 15 (27) 1 (13)
SI on HAP phase
 Hypointense – 3 (5) 3 (5) –
 Isointense 5 (100) 59 (92) 51 (91) 8 (100)
 Hyperintense – 2 (3) 2 (4) –
SI on PVP phase
 Hypointense – 9 (14) 8 (14) 1 (13)
 Isointense 5 (100) 55 (86) 48 (86) 7 (87)
 Hyperintense – – – –
SI on 3-min late phase
 Hypointense 2 (40) 13 (20) 12 (21) 1(13)
 Isointense 3 (60) 49 (77) 42 (75) 7 (87)
 Hyperintense – 2 (3) 2 (4) –
SI on 20-min HB phase
 Hypointense 5 (100) 25 (39) 25 (45) –
 Isointense – 15 (24) 12 (21) 3 (37)
 Hyperintense – 24 (37) 19 (34) 5 (63)
Baseline group
 1 2 (40) 7 (11) 7 (12) –
 2 – 23 (36) 18 (32) 5 (63)
 3 3 (60) 17 (26.5) 15 (27) 2 (25)
 4 – 4 (6) 4 (7) –
 5 – 1 (1.5) 1 (2) –
 6 – 12 (19) 11 (20) 1 (12)
Other nodules
 Yes 4 (80.0) 27 (42) 22 (39) 5 (63)
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could help to identify those patients at higher risk for HCC 
development.
In conclusion, this study demonstrated that indeterminate 
hepatocellular nodules in cirrhotic patients rarely progress 
into hypervascular HCCs. Nodules with baseline hepato-
biliary phase hypointensity and increase in size at follow-
up might be prone to become hypervascular HCCs. A Gd-
EOB-DTPA-enhanced MRI follow-up could represent the 
best option for the management of indeterminate hepatocel-
lular nodules on Gd-EOB-DTPA-enhanced MRI.
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